These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 12457297)

  • 1. Sibutramine: its mode of action and efficacy.
    Finer N
    Int J Obes Relat Metab Disord; 2002 Dec; 26 Suppl 4():S29-33. PubMed ID: 12457297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure].
    Astrup A
    Acta Med Austriaca; 1998; 25(4-5):146-9. PubMed ID: 9879391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
    Van Gaal LF; Wauters MA; De Leeuw IH
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():35-40. PubMed ID: 9792480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM;
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.
    Astrup A; Lundsgaard C
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():29-34. PubMed ID: 9792479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The new role of pharmacotherapy for weight reduction in obesity.
    Fernstrom MH; Fernstrom JD
    Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.
    Finer N; Ryan DH; Renz CL; Hewkin AC
    Diabetes Obes Metab; 2006 Mar; 8(2):206-13. PubMed ID: 16448525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
    Elfhag K; Finer N; Rössner S
    Diabetes Obes Metab; 2008 Jun; 10(6):498-505. PubMed ID: 17593239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
    Early JL; Apovian CM; Aronne LJ; Fernstrom MH; Frank A; Greenway FL; Heber D; Kushner RF; Cwik KM; Walch JK; Hewkin AC; Blakesley V
    Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery and status of sibutramine as an anti-obesity drug.
    Luque CA; Rey JA
    Eur J Pharmacol; 2002 Apr; 440(2-3):119-28. PubMed ID: 12007530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sibutramine--a review of clinical efficacy.
    Lean ME
    Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S30-6; discussion 37-9. PubMed ID: 9130039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight loss can be as simple as 10, 20, 30--Knoll launches blueprint for the use of sibutramine in weight management.
    Cardiovasc J S Afr; 2001; 12(5):286-7. PubMed ID: 11924520
    [No Abstract]   [Full Text] [Related]  

  • 15. Metabolic benefits associated with sibutramine therapy.
    Krejs GJ
    Int J Obes Relat Metab Disord; 2002 Dec; 26 Suppl 4():S34-7. PubMed ID: 12457298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term pharmacotherapy for obesity.
    Klein S
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orlistat and sibutramine beyond weight loss.
    Mannucci E; Dicembrini I; Rotella F; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term medication use and weight loss maintenance: an observational study.
    Womble LG; Wadden TA; Berkowitz RI; Sarwer DB; Rothman RA
    Obes Res; 2001 Oct; 9(10):652-3. PubMed ID: 11595785
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.